Table 1.

Summary of select patient characteristics for surveyed sample cohort

Characteristic	All patients (n = 122)	ALL (n = 12)	AML (n = 58)	CLL (n = 42)	MPN or MDS/MPN (n = 10)
Sex (n evaluable)	n = 116	n = 12	n = 56	n = 42	n = 6
Female	59	8	30	20	1
Male	57	4	26	22	5
Age, y (n evaluable)	n = 106	n = 9	n = 54	n = 37	n = 6
Median	62.1	29.7	53.7	65.9	60.7
Range	5.5–83.8	5.5–70.2	8.2–83.8	44.7–79.4	35.2–74.9
Sample type (n evaluable)	n = 122	n = 12	n = 58	n = 42	n = 10
Peripheral blood	86	7	31	41	7
Bone marrow aspirate	34	5	25	1	3
Leukapheresis	2	0	2	0	0
WBC count (n evaluable)	n = 115	n = 9	n = 55	n = 42	n = 9
Median, ×1,000/µL	42.9	60.0	34.6	45.8	92.7
Range, ×1,000/µL	0.5–309	10.3–169	0.5–240	5.8–309	26.3–240

In total, primary samples from 122 patients with a variety of hematologic malignancies were screened for ex vivo sensitivity to inhibitor combinations.